Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Glucagon (GlucaGen / Baqsimi) vs Insulin Lispro (Humalog)
An educational, source-based comparison of Glucagon (GlucaGen / Baqsimi) and Insulin Lispro (Humalog) — how each peptide works, what it's researched for, and what to know before going deeper.
29-amino-acid peptide hormone for severe hypoglycemia.
Pancreatic alpha-cell peptide hormone that activates hepatic glucagon receptors, stimulating glycogenolysis and gluconeogenesis to raise blood glucose; also relaxes GI smooth muscle (used in radiology).
- Severe hypoglycemia (T1D/T2D)
- Beta-blocker overdose
- GI motility (imaging adjunct)
- • FDA-approved.
- • Nausea/vomiting common after recovery.
Recombinant insulin analog with reversed lysine and proline at B28/B29, reducing self-association so it acts within ~15 minutes for postprandial glucose control.
- Prandial coverage in T1D/T2D
- Insulin pump therapy
- Hyperglycemic crises (with caution)
- • FDA-approved.
- • Hypoglycemia risk if meal delayed or skipped.
Glucagon (GlucaGen / Baqsimi) vs Insulin Lispro (Humalog) — Key differences
- Class: Glucagon (GlucaGen / Baqsimi) is classified as Counter-regulatory Hormone · Endocrine, while Insulin Lispro (Humalog) is Insulin Analog · Endocrine.
- Primary research focus: Glucagon (GlucaGen / Baqsimi) — severe hypoglycemia (t1d/t2d); Insulin Lispro (Humalog) — prandial coverage in t1d/t2d.
- Tag: FDA-Approved · Emergency vs FDA-Approved · Diabetes.